← Back to Dashboard
Litigation Stage Tracker
Early / MonitoringEmerging
Formation
Active Litigation
Maturation
<45
45–55
55–70
70+
Proton Pump Inhibitors
ClosedFLATMDL 2789Pharma
12,000+
Total Cases
Causation
Long-term use of proton pump inhibitors is linked to chronic kidney disease, acute interstitial nephritis, and end-stage renal failure. A 2016 JAMA Internal Medicine study found 20-50% increased risk of chronic kidney disease with PPI use. The mechanism involves PPI-induced magnesium depletion, direct nephrotoxicity, and chronic interstitial inflammation. Plaintiffs allege manufacturers knew of kidney injury signals from post-marketing surveillance and failed to update labels.
Defendants
| Entity | Role | Note |
|---|---|---|
| AstraZeneca | Manufacturer | Nexium (esomeprazole) and Prilosec (omeprazole) — primary defendant |
| Pfizer Inc. | Manufacturer | Protonix (pantoprazole) — co-defendant |
| Procter & Gamble | Marketer | Marketed OTC Prilosec under consumer health division |
| Takeda Pharmaceutical | Manufacturer | Prevacid (lansoprazole) — co-defendant |
Litigation Timeline
2016
JAMA Internal Medicine: 20-50% increased CKD risk with PPI use
2019
Bellwether case selection completed
2020
First bellwether trial scheduled — delayed by COVID-19
2022-2023
Settlement programs resolve majority of cases
2025-2026
12,000+ cases filed — most resolved. Monitoring residual claims
Intelligence Signals
No signals yet. Signals populate automatically when scrapers run.
Key Facts
- Status
- active
Geographic Exposure
·D.N.J. (MDL 2789, Judge McNulty)
·Nationwide filing — all 50 states
·Most cases resolved through settlement programs
Eligibility Criteria
- ✓Used a PPI (Nexium, Prilosec, Prevacid, Protonix, or generic) for 1+ years
- ✓Diagnosed with chronic kidney disease, acute kidney injury, or renal failure
- ✓Kidney injury occurred during or after long-term PPI use
- ✓No pre-existing kidney disease before PPI use